The US Preventive Services Task Force has never evaluated a multicancer screening test for endorsement, which may make the process even longer, said Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco.
Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco, talks about the 2 main paths for multicancer early detection (MCED) tests to be covered by Medicare.
Transcript
What needs to happen for MCED tests to receive an endorsement by the USPSTF and/or Medicare coverage? Do you think one path is more likely than the other?
The Medicare population is obviously a logical target for MCED tests, given that advancing age is a powerful predictor of increased risk of cancer. I think there's really 2 possible paths to Medicare coverage. One would be facilitating passage of new legislation that creates a specific screening exception for MCED screening tests, and the second would be to get a US Preventive Services Task Force [USPSTF] rating of A or B. That's a pretty long process—highly evidence-based—and it's worth pointing out that, to date, the USPSTF has never had to evaluate a multicancer screening test. The paradigm is typically 1 test, 1 cancer, so [the process comes] with all those caveats.
It's also important to point out that, regardless of either of those 2 pathways, both of those strategies would still require a national coverage determination before Medicare beneficiaries would obtain access through traditional Medicare. In terms of which one is longer, both paths have tremendous uncertainty. Because of the reason that multicancer early detection is an unprecedented testing paradigm, I think it's really difficult to predict which 1 of the 2 pathways is more likely to succeed, but hopefully I've pointed out how they're interrelated.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More